130 related articles for article (PubMed ID: 12562652)
21. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
22. Weekly CODE chemotherapy with recombinant human granulocyte colony-stimulating factor for relapsed or refractory small cell lung cancer.
Sato K; Tsuchiya S; Minato K; Sunaga N; Ishihara SI; Makimoto T; Naruse I; Hoshino H; Watanabe S; Saitoh R; Mori M
Oncol Rep; 2000; 7(5):1135-9. PubMed ID: 10948352
[TBL] [Abstract][Full Text] [Related]
23. CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial.
Sandler A; Blanke C; Monaco F; Carey MA; Ansari R; Fisher B; Spiridonidis CH; Einhorn L; Nichols C
Am J Clin Oncol; 1998 Jun; 21(3):294-7. PubMed ID: 9626802
[TBL] [Abstract][Full Text] [Related]
24. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
[TBL] [Abstract][Full Text] [Related]
25. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
[TBL] [Abstract][Full Text] [Related]
26. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
[TBL] [Abstract][Full Text] [Related]
27. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.
Schröder CP; de Vries EG; Mulder NH; Willemse PH; Sleijfer DT; Hospers GA; van der Graaf WT
J Antimicrob Chemother; 1999 May; 43(5):741-3. PubMed ID: 10382902
[TBL] [Abstract][Full Text] [Related]
28. Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung.
de Jongh CA; Wade JC; Finley RS; Joshi JH; Aisner J; Wiernik PH; Schimpff SC
J Clin Oncol; 1983 May; 1(5):302-7. PubMed ID: 6321684
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial.
Schuette W; Nagel S; von Weikersthal LF; Pabst S; Schumann C; Deuss B; Salm T; Roscher K; Dickgreber N
J Thorac Oncol; 2011 Dec; 6(12):2090-6. PubMed ID: 22052225
[TBL] [Abstract][Full Text] [Related]
30. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
[TBL] [Abstract][Full Text] [Related]
31. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.
Trillet-Lenoir V; Green J; Manegold C; Von Pawel J; Gatzemeier U; Lebeau B; Depierre A; Johnson P; Decoster G; Tomita D
Eur J Cancer; 1993; 29A(3):319-24. PubMed ID: 7691119
[TBL] [Abstract][Full Text] [Related]
32. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.
Doyle JJ; Dezii CM; Sadana A
Semin Oncol; 1996 Dec; 23(6 Suppl 13):51-60. PubMed ID: 8996576
[TBL] [Abstract][Full Text] [Related]
33. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
[TBL] [Abstract][Full Text] [Related]
34. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
[TBL] [Abstract][Full Text] [Related]
35. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
Drummond M; Davies L
Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.
Herbst C; Naumann F; Kruse EB; Monsef I; Bohlius J; Schulz H; Engert A
Cochrane Database Syst Rev; 2009 Jan; (1):CD007107. PubMed ID: 19160320
[TBL] [Abstract][Full Text] [Related]
37. Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Samantas E; Pectasides D; Pavlidis N; Kalofonos C; Klouvas G; Panoussaki E; Tsiakopoulos E; Poulakis N; Fountzilas G
Am J Clin Oncol; 1999 Feb; 22(1):87-93. PubMed ID: 10025390
[TBL] [Abstract][Full Text] [Related]
38. [Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501)].
Gervais R; Le Guen Y; Le Caer H; Paillotin D; Chouaid C;
Rev Mal Respir; 2007 May; 24(5):653-8. PubMed ID: 17519820
[TBL] [Abstract][Full Text] [Related]
39. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics.
Sculier JP; Paesmans M; Lecomte J; Van Cutsem O; Lafitte JJ; Berghmans T; Koumakis G; Florin MC; Thiriaux J; Michel J; Giner V; Berchier MC; Mommen P; Ninane V; Klastersky J;
Br J Cancer; 2001 Nov; 85(10):1444-51. PubMed ID: 11720426
[TBL] [Abstract][Full Text] [Related]
40. Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.
Sulpher J; Giguere P; Hopkins S; Dent S
Support Care Cancer; 2016 Jul; 24(7):3185-9. PubMed ID: 26939922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
